Marella Thorell - 21 Mar 2022 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Reporting relationship: Chief Accounting Officer
Issuer ticker: CNTA
Reported as of: 21 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Mar 2022, 16:56:30 UTC
Prior SEC filing: 03 Feb 2022
Next SEC filing: 10 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Marella Thorell

Key filing fact

Marella Thorell filed Form 4 for Centessa Pharmaceuticals plc (CNTA) on 23 Mar 2022.

Key facts

This page summarizes Marella Thorell's Form 4 filing for Centessa Pharmaceuticals plc (CNTA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Mar 2022, 16:56.

Change

Previous filing in this sequence was filed on 03 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNTA transaction

Ordinary Shares

Other

Transaction value: $0
Shares: +52,101
Change %: +5210%
Price: $0.000000
Shares after: 53,101
Date: 21 Mar 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares ("ADSs"), each of which currently represents one Ordinary Share.

Footnote F2

Represents ADSs received by the Reporting Person, for no consideration, pursuant to contingent value rights granted to the Reporting Person in January 2021.